KYTX: Miv-cel shows transformative results in SPS and gMG, with regulatory and commercial milestones ahead
Transformative cell therapy miv-cel is advancing toward regulatory approval for Stiff Person Syndrome, with strong safety and efficacy data and a rolling BLA submission expected to complete in Q4. Expansion into gMG and progressive MS is underway, with pivotal trials and commercialization plans tar…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.